Document:

Amendment No. 2 to Collaboration Research, Development and License Agreement

 Exhibit 10.25 
 SECOND AMENDMENT TO 
 COLLABORATIVE RESEARCH, DEVELOPMENT 
 AND LICENSE AGREEMENT 
 THIS SECOND AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT
(the “Second Amendment”) is entered into as of February 28, 2006 (the “Second Amendment Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a
Delaware corporation (“ACADIA”) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES LLC a Delaware limited liability company, (“Allergan”), with offices at 2525 Dupont
Drive, Irvine, CA 92623, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan. 
 RECITALS 
 WHEREAS, the parties previously
entered into that certain Collaborative Research, Development and License Agreement, dated September 24, 1997 (as amended by the First Amendment described below, the “1997 Agreement”), pursuant to which the parties
conducted collaborative research regarding, among other things, receptor selective compounds with the goal of establishing drug discovery programs related to such receptor selective compounds; 
 WHEREAS, the 1997 Agreement was first amended on March 27, 2003 (the “First
Amendment”) to continue the collaboration under the 1997 Agreement with respect to alpha adrenergic receptors and on the same date the parties entered into a new Collaborative Research, Development and License Agreement (the
“2003 Agreement”) regarding ACADIA’s chemical-genomics assets; 
 WHEREAS,
the Research Terms of both of the 1997 Agreement and the 2003 Agreement (collectively, the “Agreements”) will expire on March 27, 2006; and 
 WHEREAS, the parties wish to continue their research collaboration under the Agreements on alpha adrenergic receptors and this Second Amendment provides for further research on alpha adrenergic
receptors pursuant to the terms of the Agreements as amended by the terms set forth below (the “Alpha Adrenergic Research Program”); and 
 WHEREAS, the parties may wish to continue to collaborate on other receptor selective compounds included in ACADIA’s chemical-genomics assets on the terms set forth below.

 NOW THEREFORE, in consideration of the foregoing and the covenants and premises contained in this
Second Amendment, the parties hereby agree as follows: 
 1. Alpha Adrenergic Research Program Continuation. The Alpha Adrenergic Research Program
shall continue with contribution from both Allergan and ACADIA, as applicable, under the terms of the Agreements, as amended by this Second Amendment. 

 The Alpha Adrenergic Research Program shall be managed by the Joint Research Committee as set forth in Section 2 of
the 2003 Agreement. Research funding for the Alpha Adrenergic Research Program shall be at the adjusted rate provided for in Section 8.4 of the 2003 Agreement for the appropriate year of the Research Term. The Research Term of the Agreements
with respect to the Alpha Adrenergic Research Program shall be extended to cover the period beginning March 27, 2006 and ending March 27, 2008 (the “Extension Period”). All of Allergan’s rights under the 1997 Agreement with
respect to receptors and receptor subtypes (other than alpha adrenergic receptors) shall expire on March 27, 2006, subject to surviving obligations (other than ACADIA’s rights to any ACADIA Designated Use) under Section 11.4 of the
1997 Agreement. Notwithstanding the terms of the Agreements and this Amendment, Allergan and ACADIA agree to discuss, in good faith, [ *** ]. 
 2.
Extension Program(s). ACADIA hereby grants Allergan the right to request, during the Extension Period, that up to three Target/Chemistries (as defined in the 2003 Agreement), which were identified as such as of March 27, 2006, be designated as
Selected 
 Target/Chemistries (as defined in the 2003 Agreement) in accordance with Section 5.1 of the 2003 Agreement; provided that the decision to make a
Target/Chemistry a Selected Target Chemistry (and thereby an Extension Program) shall be at [ *** ]. Allergan’s right to request such Target/Chemistries shall expire on March 27, 2008 (each, an “Extension Program”). 
 3. FTE Funding. During the Extension Period, Allergan shall fund a minimum of [ *** ] ACADIA FTEs (at the rate provided for by Section 8.4(a) of the 2003
Agreement). In the event Allergan chooses one or more Extension Programs, the number of additional FTEs and the duration of the research term for the Extension Program shall be mutually agreed to by the parties. The parties agree that Allergan shall
be obligated to pay ACADIA research funding payments for such Extension Program(s) at a rate not to exceed the rate provided for in Section 8.4(a) of the 2003 Agreement. The allocation of FTEs between such Extension Program(s) and the Alpha
Adrenergic Research Program shall be decided by JRC, provided however in the event that the parties do not agree on such allocation, notwithstanding Section 15.2 of the 2003 Agreement, [ *** ]. 
 4. Access to ACADIA Technology. Except as set forth herein with regard to alpha adrenergic compounds and receptors and Extension Program(s), effective
March 27, 2006, Allergan shall no longer have any rights with respect to the ACADIA Technology (as defined in the 2003 Agreement) or ACADIA’s interest in Collaboration Technology (as defined in the 2003 Agreement), and all rights to
ACADIA Technology and ACADIA’s interest in Collaboration Technology and all Collaboration Targets/Chemistries (as defined in the 2003 Agreement) shall revert to ACADIA. Allergan shall have no further obligation to pay any fee for access to the
ACADIA Technology and ACADIA agrees that Allergan has paid all fees for such access that were obligated to be paid under Section 8.1 of the 2003 Agreement. 
 5. Return of Information. Each party will return any technology or know-how and Confidential Information of the other party as required by Section 13.5 of the 2003 

 
Agreement; with the exception of any technology know-how or Confidential Information related to the Alpha Adrenergic Research Program and the
Chemical-Genomics Asset List (as defined in the 2003 Agreement). 
 6. License to ACADIA. Allergan hereby grants to ACADIA an exclusive,
worldwide, royalty-free license under the Allergan Technology (as defined in the 2003 Agreement) and under Allergan’s interest in the Collaboration Technology to make, have made and use the Selected Target/Chemistry identified below in all
fields of use, and to make, have made, use, sell, offer for sale and import ACADIA Royalty-Free Products (as defined in the 2003 Agreement) based on the Selected Target/Chemistry identified below in all fields of use. Such license is limited to the
following Selected Target/Chemistry: [ *** ]. 
 7. FULL FORCE AND EFFECT. Except as
specifically amended by this Second Amendment, each of the 1997 Agreement and the 2003 Agreement shall remain in full force and effect. If there is any inconsistency or conflict between any provision in this Second Amendment and any provision in the
1997 Agreement and/or the 2003 Agreement, the provision in this Second Amendment shall control. 
 8. MISCELLANEOUS. This Second
Amendment may be signed in counterparts, each of which shall be deemed an original, all of which taken together shall be deemed one instrument. This Second Amendment shall be governed by the laws of the State of California as such laws are applied
to contracts entered into or to be performed entirely within such state. 
 IN WITNESS
WHEREOF, the parties hereto have duly executed this Second AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE
AGREEMENT. 
  

			
	ACADIA PHARMACEUTICALS INC.	  	ALLERGAN SALES LLC, a Delaware limited liability company, a successor in interest of
		  	        VISION PHARMACEUTICALS L.P.,
		  	A Texas limited partnership, dba Allergan, by Allergan General, Inc., its general partner

  

									
	By:	 	 /s/ Uli Hacksell
	  		  	By:	  	 /s/ David M. Lawrence

	Name:	 	Uli Hacksell, Ph.D.	  		  	Name:	  	David M. Lawrence
	Title:	 	Chief Executive Officer	  		  	Title:	  	Sr. Vice President Corporate Development 

  

							
	Guarantee of performance by:	 		 	
			
	ALLERGAN, INC.	 		 	
				
	By:	 	 /s/ James M. Hindman
	 		 	
	Name:	 	James M. Hindman	 		 	
	Title:	 	SR VP TREASURY, RISK, INVESTOR RELATIONSDescription of Executive Officer Annual Incentive Cash Compensation Program

 Exhibit 10.26 
 ACADIA Pharmaceuticals Inc. 
 Description of Executive Officer Annual Incentive Cash Compensation
Program 
 The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of ACADIA
Pharmaceuticals Inc. (the “Company”) has recommended to the Board, and the Board has approved, incentive cash compensation for the Company’s executive officers pursuant to an annual incentive cash compensation program. The program
provides for an annual incentive cash compensation target equal to a percentage of each executive’s base salaries as follows: 30% for Uli Hacksell, CEO; 26.5% for Mark R. Brann, President and CSO; 23.5% for Thomas H. Aasen, Vice President and
CFO and Brian Lundstrom, Senior Vice President, Business Development; and 20% for Bo-Ragnar Tolf, Vice President, Chemistry. 
 Under the
program, after the completion of each fiscal year the Committee recommends to the Board for approval for each executive a bonus that will be equal to an amount from 0 to 150% of the applicable target amount. In making its recommendations, the
Committee assesses the level of achievement of specific criteria by the executive and the Company. These criteria include the achievement of research and development milestones, including the advancement of the Company’s clinical programs and
the Company’s preclinical assets toward clinical development; and other criteria the disclosure of which would reveal confidential business information and plans of the Company.Amendment, dated as of Nov. 18, 2005, to Restated Deferred Compensation Plan

 Exhibit 10.12(b) 
  
 ACTION BY AUTHORIZED PERSON 
 TO AMEND THE 
 CB RICHARD ELLIS DEFERRED COMPENSATION PLAN 
  
 WHEREAS, CB Richard Ellis Group, Inc. (the “Company”) currently
maintains the CB Richard Ellis Deferred Compensation Plan (as amended, the “Plan”); 
  
 WHEREAS, Brett White, the Company’s Chief Executive Officer and a member of the Company’s Board of Directors (“Authorized Person”), has been authorized to act on behalf of the Board of Directors to
amend the Plan; and 
  
 WHEREAS, IRS Notice 2005-1, Q&A 20,
permits the Company to amend the Plan to allow participants to revoke their deferral elections with respect to 2005 deferrals. 
  
 NOW, THEREFORE, BE IT RESOLVED, that effective November 18, 2005, the Plan shall be amended by the addition of the following Section 13 at the
end thereof: 
  
 “13. TRANSITION RULE
ELECTION. 
  
 Notwithstanding any other provision
of the Plan, a Participant who has a Deferral election in effect for the Plan Year ending December 31, 2005 may make a one-time irrevocable election (the “Transition Rule Election”) to cancel that Deferral election on before
November 30, 2005. If a Participant makes the Transition Rule Election, the Employer will cause the Participant to receive a refund of Deferrals credited to his Account during 2005 through November 30, 2005, including any applicable gain
or loss, and will cease Deferrals from the Participant’s Compensation for December 2005. The Transition Rule Election applies to Deferrals of salary, commissions and any bonus or other Compensation paid in 2005 (but not any bonus earned in 2005
that is payable in 2006). Any amounts to be refunded to the Participant in accordance with the Transition Rule Election will be paid to the Participant on or before December 31, 2005, and will be reported to the Participant for federal and
state income tax purposes as income for taxable year 2005.” 
  
 RESOLVED, FURTHER, that any officer of the Company, or any successor thereof, is hereby authorized, directed and empowered, for and on behalf of the Company, to take any and all such action and execute and deliver all such documents as may
be necessary or advisable to implement the foregoing resolutions, including (without limitation) the preparation and distribution of employee communication material informing employees of the terms of the amendment to the Plan and the preparation,
execution and delivery of all other instruments and documents which each such officer may, in his or her discretion, deem necessary or advisable to carry our the intent of the foregoing resolutions. Any actions by officers of the Company or their
delegates that have already been taken to carry out the intent of these resolutions are hereby ratified and confirmed. 
  
 IN WITNESS WHEREOF, the undersigned hereby executes this resolution. 
  

									
				
	 Date: December 19, 2005
	 	 	 	 	 	 /s/ Brett White

	 	 	 	 	 	 	 	 	 Brett White
 Chief Executive Officer,
 CB Richard Ellis Group, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]